Not yet recruitingPhase 4

Impact of Glucagon-like Peptide-1 (GLP-1) Analogs on Disease Outcomes in Psoriatic Arthritis: A Pragmatic Randomized Controlled Trial

Lead sponsor

Medical College of Wisconsin

Asset

GLP-1 / incretin class catch-all

Listed sites

Recruiting sites

Estimated enrollment

Study population

Eligibility highlights

Primary endpoints

•Change from the baseline Minimal Disease Activity (MDA) Scores•Proportion of Patients who Achieve Disease Activity in Psoriatic Arthritis

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07111494

Org study IDPRO55130

Timeline

Milestones

Study first posted2025-08-08actual

Last update posted2025-08-13actual

Study start2025-10-15estimated

Primary completion2026-10-15estimated

Study completion2028-10-15estimated

Assets

Investigational agents

GLP-1 / incretin class catch-all

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Adult patients (age 18 and older) who present to rheumatology clinic

•Participants must be able to read, understand, and provide documented informed consent as approved by the Institutional Review Board (IRB).

•Meet the Classification of Psoriatic Arthritis (CASPAR) criteria for PsA

•Participants must have a Body Mass Index (BMI) of 30kg/m^2

•Participants must be treated for PsA in accordance with guidelines

•Have not achieved MDA in PsA patients

•Have a minimum TJC > 1 and SJC > at baseline

•Eligible for GLP-1 agonist treatment in accordance with Food Drug Administration (FDA) labeling as determined by the investigator.

Exclusion criteria

•Any prior use of GLP-1 agonists

•Inability to provide informed consent

•Current participation in another PsA study

•Treatment initiation by GLP-1 agonists contraindicated by FDA

•Patients with hemoglobin A1c (HbA1c) > 10 at baseline

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other clinical outcomes

Other (unclassified)

Other clinical outcomes

1 endpoint

Primary/protocol endpoint

Proportion of Patients who Achieve Disease Activity in Psoriatic Arthritis (DAPSA) Remission with GLP-1 Agonists Vs. Nutrition Counseling at Week 12 and 24

Time frame:Week 12 and 24

threshold achievement, improvement

Other (unclassified)

1 endpoint

Primary/protocol endpoint/low confidence

Change from the baseline Minimal Disease Activity (MDA) Scores at Week 12 and 24 with GLP-1 Agonists vs Nutrition Counseling

Time frame:Week 12 and 24

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.